Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

By D. A. Shapiro, Sean M Renock, Elaine G Arrington, L. Chiodo, Li-xin Liu, David R. Sibley, Bryan L. Roth, R. Mailman. Neuropsychopharmacology, 2003

980 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/99c64651264f14f1fffc1a63d4c20a8e274369da

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Raymond C. Stevens
2. David E. Gloriam
3. Brian K. Kobilka
4. Vsevolod Katritch
5. Bryan L. Roth
6. David E. Nichols
7. Arthur Christopoulos
8. M. von Zastrow

In Molecular Biology

1. Vsevolod Katritch
2. David E. Gloriam
3. Raymond C. Stevens
4. Brian K. Kobilka
5. Bryan L. Roth
6. Kasper Harpsøe
7. Arthur Christopoulos
8. Shuguang Yuan

Citations in the corpus

• Functional Selectivity and Classical Concepts of Quantitative Pharmacology (2007, background): “Moreover, aripiprazole antagonizes both D2 receptor-medi- ated GTP S binding and GIRK channel activity (Shapiro et al., 2003) while acting as a full agonist in situ for D2-mediated inhibition of tyrosine hydroxylase (C. Prioleau, C. P. Lawler, and R. B. Mailman, unpublished observation).”
• 5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology (2018, positive): “Therefore, incorporating functional selectivity or biased agonism into a drug’s polypharmacological profile can often lead to novel avenues of therapeutic potential, as observed with aripiprazole, a polypharmacological drug that demonstrates functional selectivity (Shapiro et al., 2003; Tuplin and H”